Cardiomagnet tab. p / o captivity. 150mg + 30.39 mg # 30

Film-coated tablets, containing 75 mg / 15.2 mg of acetylsalicylic acid and magnesium hydroxide, respectively: film-coated tablets, white in the shape of a stylized heart" Film-coated tablets containing 150 mg / 30.39 mg of acetylsalicylic acid and magnesium hydroxide, respectively: film-coated tablets, white, oval in shape with a line on one side.

Pharmaco-therapeutic group

N4 Primary prevention of cardiovascular diseases such as thrombosis and acute heart failure in the presence of risk factors (eg diabetes mellitus, hyperlipidemia, arterial hypertension, obesity, smoking, old age).

Prevention of recurrent myocardial infarction and blood vessel thrombosis.

Prevention of thromboembolism after surgical interventions on the vessels (coronary artery bypass grafting, percutaneous transluminal coronary angioplasty).

Unstable angina.

Application during pregnancy and during breastfeeding

The use of large doses of salicylates in the first 3 months of pregnancy is associated with an increased incidence of fetal defects. In the second trimester of pregnancy, salicylates can be prescribed only with a rigorous assessment of the risks and benefits. In the last trimester of pregnancy, salicylates in a high dose (more than 300 mg / day) cause inhibition of labor, premature closure of the ductus arteriosus in the fetus, increased bleeding in the mother and fetus, and administration just before childbirth can cause intracranial hemorrhage, especially in premature babies. The appointment of salicylates in the last trimester of pregnancy is contraindicated. The available clinical data are insufficient to establish the possibility or impossibility of using the drug during breastfeeding.Before prescribing acetylsalicylic acid during lactation, the potential benefit of drug therapy should be assessed in relation to the potential risk to infants.

Dosage form

Film-coated tablets 75 mg + 15.2 mg and 150 mg + 30.39 mg 30 or 100 tablets each in brown glass vials, sealed with a white screw cap (made of polyethylene), with a built-in removable capsule with silica gel and a ring providing control of the first autopsy.

A label is attached to each bottle.

One bottle with instructions for use is placed in a cardboard box.

Shelf life

3 years.

Do not use after the expiration date.

Category

Cardiovascular pathology

Dosage

150mg + 30.39mg

Structure

Film-coated tablets, white, oval in shape, with a line on one side.

Active ingredients: acetylsalicylic acid 150 mg in 1 tablet.

Magnesium hydroxide 30.39 mg in 1 tablet.

Excipients: corn starch, microcrystalline cellulose, magnesium stearate, potato starch, hypromellose (methylhydroxypropylcellulose 15), macrogol (propylene glycol), talc.

Indications

primary prevention of cardiovascular diseases, such as thrombosis and acute heart failure in the presence of risk factors (for example, diabetes mellitus, hyperlipidemia, arterial hypertension, obesity, smoking, old age)

prevention of repeated myocardial infarction and blood vessel thrombosis

prevention of thromboembolism after surgical interventions on the vessels (coronary artery bypass grafting, percutaneous transluminal coronary angioplasty)

unstable angina.

INN / Active ingredient

Magnesium hydroxide + acetylsalicylic acid

Storage conditions and periods

In a dark place at a temperature not exceeding 25 ° C.

Keep out of the reach of children.

Contraindications

Hypersensitivity to ASA, excipients of the drug and other NSAIDs, cerebral hemorrhage

bleeding tendency (vitamin K deficiency, thrombocytopenia, hemorrhagic diathesis)

bronchial asthma induced by the intake of salicylates and NSAIDs

erosive and ulcerative lesions of the gastrointestinal tract (in the acute phase)

gastrointestinal bleeding

severe renal failure (creatinine clearance less than 10 ml / min.)

pregnancy (I and III trimesters)

lactation period

deficiency of glucose-6-phosphate dehydrogenase

simultaneous reception with methotrexate (more than 15 mg per week)

children under 18 years of age.

Specifications

Scope of the medicinal product

General

Release form

Tablet

Manufacturer country

Germany

Package quantity, pcs

thirty

Scope of application

Cardiology

Vacation conditions

Without recipe

Brand name

Takeda

The amount of the dosage form in the primary package

30 pcs.

Primary packaging type

Brown glass bottle

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Antiplatelet agent

Anatomical and therapeutic characteristics

B01AC30 Platelet aggregation inhibitors in combination

Dosage form

Film-coated tablets

Expiration date in days

1095

Dosage (volume) of the substance in the preparation

Acetylsalicylic acid 150 mg, magnesium hydroxide 30.39 mg

Package weight, g

75

Category

:

Improving blood circulation

,

Angioprotectors and microcirculation correctors

,

Lipid-lowering drugs

,

Hematopoietic stimulants

Mode of application

:

The tablets are swallowed whole with water. If desired, the tablet can be broken in half, chewed or pre-ground. Primary prevention of cardiovascular diseases such as thrombosis and acute heart failure in the presence of risk factors (for example, diabetes mellitus, hyperlipidemia, arterial hypertension, obesity, smoking, old age) 1 tablet of Cardiomagnyl containing ASA at a dose of 150 mg on the first day, then 1 tablet of Cardiomagnyl containing ASA at a dose of 75 mg 1 time per day. Prevention of recurrent myocardial infarction and blood vessel thrombosis 1 tablet of Cardiomagnyl containing ASA at a dose of 75 - 150 mg 1 time per day. Prevention of thromboembolism after surgical interventions on the vessels (coronary artery bypass grafting, percutaneous transluminal coronary angioplasty) 1 tablet of Cardiomagnyl,containing ASA at a dose of 75 - 150 mg 1 time per day. Unstable angina pectoris 1 tablet of Cardiomagnyl containing ASA at a dose of 75–150 mg 1 time per day.

Information on technical characteristics, delivery set, country of manufacture "